Related coverage linked through entity extraction aliases.
Mar 22, 2026
Prothena reported Q4 and full year 2025 financial results with $308.4 million in cash as partners Roche and Novo Nordisk initiated Phase 3 trials for prasinezumab and coramitug, both expected to complete in 2029.
Feb 21, 2026
Prothena reported Q4 2025 adjusted loss of 45 cents per share, meeting estimates, while ending the year with $308.4 million in cash. Roche and Novo Nordisk advanced partnered programs prasinezumab and coramitug into Phase III trials.
Feb 19, 2026
Korsana Biosciences launched from stealth with $175 million in funding to advance KRSA-028, a monoclonal antibody targeting amyloid beta plaques in Alzheimer's disease using a blood-brain barrier shuttle technology.
